Sarepta Therapeutics Inc [SRPT] stock prices are down -0.65% to $119.47 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SRPT shares have lost -4.02% over the last week, with a monthly amount glided 12.05%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on November 27, 2024, when Needham reiterated its Buy rating and also revised its price target to $202 from $205. Previously, H.C. Wainwright started tracking the stock with Sell rating on November 25, 2024, and set its price target to $80. On November 07, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $167 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $165 on October 21, 2024. RBC Capital Mkts upgraded its rating to Outperform for this stock on July 29, 2024, but kept the price target unchanged to $182. In a note dated June 26, 2024, Citigroup downgraded an Neutral rating on this stock and boosted its target price from $172 to $176.
The stock price of Sarepta Therapeutics Inc [SRPT] has been fluctuating between $89.92 and $173.25 over the past year. Currently, Wall Street analysts expect the stock to reach $187.2 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $119.47 at the most recent close of the market. An investor can expect a potential return of 56.69% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
The Sarepta Therapeutics Inc [NASDAQ:SRPT] reported sales of 1.64B for trailing twelve months, representing a surge of 40.79%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.05%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is 0.07%. To continue investigating profitability, this company’s Return on Assets is posted at 0.03, Equity is 0.12 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 117.46 points at the first support level, and at 115.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 121.99, and for the 2nd resistance point, it is at 124.51.
Ratios To Look Out For
It’s worth pointing out that Sarepta Therapeutics Inc [NASDAQ:SRPT]’s Current Ratio is 3.84. Further, the Quick Ratio stands at 3.03, while the Cash Ratio is 0.28. Considering the valuation of this stock, the price to sales ratio is 6.96, the price to book ratio is 9.34 and price to earnings (TTM) ratio is 99.24.
Transactions by insiders
Recent insider trading involved Wigzell Hans Lennart Rudolf, Director, that happened on Dec 12 ’24 when 10500.0 shares were sold. Director, Wigzell Hans Lennart Rudolf completed a deal on Dec 12 ’24 to buy 10500.0 shares. Meanwhile, Director Boor Kathryn Jean sold 1636.0 shares on Dec 05 ’24.
